Milyon USD cinsinden finanslar. Mali yıl Şubat - Ocak'tır.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Hasılat
15,558
15,558
14,800
13,310
10,561
10,310
Hasılat Artışı (YoY)
5%
5%
11%
26%
2%
13%
Satınalma Maliyeti
7,479
7,479
7,129
6,485
4,829
4,466
Brüt Kâr
8,079
8,079
7,671
6,825
5,732
5,843
Satış, Genel ve İdari
2,616
2,148
2,019
2,146
1,551
1,616
Araştırma ve Geliştirme
1,359
1,359
1,430
1,269
1,156
1,001
İşletme Giderleri
3,975
3,975
3,859
3,572
2,804
2,713
Diğer Finansman Gelirleri (Giderleri)
--
--
--
--
--
--
Kâr Öncesi Gelir
3,724
3,724
3,375
2,663
2,779
2,963
Kira Vergisi Gideri
588
588
661
419
524
588
Net Kâr
3,002
3,002
2,642
2,194
2,254
2,375
Net Income Growth
Kâr Artışı
14%
14%
20%
-3%
-5%
13%
Dolaşım Daki Hisse Senetleri (Dilüte Edilmiş)
486.35
486.22
485.19
483.88
468.75
456.2
Hisse Değişimi (Yıllık Üst Üste)
0%
0%
0%
3%
3%
0%
EPS (Diluted)
6.17
6.17
5.44
4.53
4.81
5.2
EPS Artışı
13%
13%
20%
-6%
-8%
13%
Öz sermaye akışı
2,563
2,563
1,506
909
1,381
1,954
Hisse Başı Öz Kaynak Akışı
--
--
--
--
--
--
Brüt Karşılık
51.92%
51.92%
51.83%
51.27%
54.27%
56.67%
Faaliyet Kâr Marjı
26.37%
26.37%
25.75%
24.44%
27.71%
30.35%
Kâr Marjı
19.29%
19.29%
17.85%
16.48%
21.34%
23.03%
Özsermaye Karlılık Oranı
16.47%
16.47%
10.17%
6.82%
13.07%
18.95%
EBITDA
5,121
4,572
4,222
3,594
3,023
3,225
EBITDA Marjinali
32.91%
29.38%
28.52%
27%
28.62%
31.28%
D&A EBITDA için
1,017
468
410
341
96
95
Faaliyet Kârı
4,104
4,104
3,812
3,253
2,927
3,130
Faaliyet Kâr Marjı
26.37%
26.37%
25.75%
24.44%
27.71%
30.35%
Verilen Vergi Oranı
15.78%
15.78%
19.58%
15.73%
18.85%
19.84%
Önemli İstatistikler
Önceki Kapanış
$111.43
Açılış fiyatı
$103.23
Günün Aralığı
$102.45 - $110.47
52 haftalık aralık
$102.45 - $184.09
İşlem hacmi
21
Ort.Hacim
3.2K
EPS (TTM)
6.17
Dividend yield
--
Piyasa Değeri
$49.7B
CSL LTD nedir?
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 32,065 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.